Bio-Techne Corp logged a -3.3% change during today's afternoon session, and is now trading at a price of $51.17 per share.
Bio-Techne Corp returned losses of -29.4% last year, with its stock price reaching a high of $80.8 and a low of $46.01. Over the same period, the stock underperformed the S&P 500 index by -45.7%. AThe company's 50-day average price was $53.81. Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. Based in Minneapolis, MN, the Mid-Cap Health Care company has 3,100 full time employees. Bio-Techne Corp has offered a 0.6% dividend yield over the last 12 months.
Wider Gross Margins Than the Industry Average of 58.93%:
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue (M) | $714 | $739 | $931 | $1,106 | $1,137 | $1,159 |
| Gross Margins | 66% | 65% | 68% | 68% | 68% | 66% |
| Net Margins | 13% | 31% | 15% | 25% | 25% | 15% |
| Net Income (M) | $96 | $229 | $140 | $272 | $285 | $168 |
| Net Interest Expense (M) | $22 | $19 | $14 | $11 | $11 | $15 |
| Depreciation & Amort. (M) | $78 | $83 | $88 | $101 | $107 | $112 |
| Diluted Shares (M) | 158 | 161 | 165 | 162 | 160 | 161 |
| Earnings Per Share | $0.61 | $1.42 | $0.85 | $1.68 | $1.78 | $1.05 |
| EPS Growth | n/a | 132.79% | -40.14% | 97.65% | 5.95% | -41.01% |
| Avg. Price | $48.74 | $61.3 | $109.7 | $97.7 | $77.16 | $51.13 |
| P/E Ratio | 77.37 | 41.14 | 121.89 | 56.47 | 42.87 | 48.24 |
| Free Cash Flow (M) | $156 | $153 | $308 | $280 | $216 | $236 |
| CAPEX (M) | $25 | $52 | $44 | $45 | $38 | $63 |
| EV / EBITDA | 34.21 | 39.63 | 52.97 | 38.66 | 30.83 | 25.85 |
| Total Debt (M) | $383 | $232 | $282 | $212 | $447 | $300 |
| Net Debt / EBITDA | 1.21 | 0.27 | 0.22 | 0.12 | 0.78 | 0.38 |
| Current Ratio | 4.43 | 4.61 | 3.81 | 4.4 | 4.37 | 3.94 |
Bio-Techne Corp has growing revenues and increasing reinvestment in the business, generally positive cash flows, and an excellent current ratio of 3.94. The company also benefits from wider gross margins than its peer group, positive EPS growth, and healthy leverage levels.
Bio-Techne Corp's Valuation Is in Line With Its Sector Averages:
Bio-Techne Corp has a trailing twelve month P/E ratio of 117.0, compared to an average of 22.94 for the Health Care sector. Based on its EPS guidance of $2.19, the company has a forward P/E ratio of 24.6. Bio-Techne Corp's PEG ratio is 8.55 on the basis of the 13.7% weighted average of the company and the broader market's EPS compound average growth rates. This suggests that the company's shares are overvalued. Furthermore, Bio-Techne Corp is likely overvalued compared to the book value of its equity, since its P/B ratio of 4.13 is higher than the sector average of 3.19. The company's shares are currently trading 192.7% below their Graham number.
Bio-Techne Corp Has an Average Rating of Buy:
The 13 analysts following Bio-Techne Corp have set target prices ranging from $53.0 to $75.0 per share, for an average of $66.23 with a buy rating. The company is trading -22.7% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
Bio-Techne Corp has an average amount of shares sold short because 3.8% of the company's shares are sold short. Institutions own 103.3% of the company's shares, and the insider ownership rate stands at 0.26%, suggesting a small amount of insider investors. The largest shareholder is Vanguard Group Inc, whose 12% stake in the company is worth $943,488,902.
